Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy

Completed · Phase 1

Conditions studied: Thrombocytopenia, Neoplasm, Cancer

In brief

The purpose of this study is to measure the therapeutic potential of Escherichia coli (E. coli) and yeast ribosomal Ribonucleic acid (RNA) fragments to maintain the production of platelets in patients undergoing cytotoxic therapy for cancer.

Key facts

Study ID

NCT01163110

Run by

Midwestern Regional Medical Center

People needed

32

Starts

2004-03-01

Expected to finish

2007-06-01

Last updated by the study team

2013-11-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• between the ages of 18 and 80
• currently receiving chemotherapy with a platelet nadir of less than or equal to 80,000
• Eastern Oncology Oncology Group (ECOG) performance status of 0, 1, 2, 3, and 4
• signed informed consent
• willing to take RealBuild and magnesium supplement and undergoing chemotherapy known to induce thrombocytopenia
• willing to stop benzodiazepines
• must be at least 6 hours post therapeutic heparin dose

You may not qualify if…

• life expectancy less than three months
• pregnant women or women of childbearing potential who refuse to use prophylaxis against pregnancy while receiving chemotherapy regimens
• patients know hypersensitive to RNA or its metabolic products
• patients requiring therapeutic heparin or benzodiazepines

Where it is running

• Midwestern Regional Medical Center — Zion, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.